KR20210029165A - 비아릴에테르형 퀴나졸린 유도체 - Google Patents

비아릴에테르형 퀴나졸린 유도체 Download PDF

Info

Publication number
KR20210029165A
KR20210029165A KR1020207038066A KR20207038066A KR20210029165A KR 20210029165 A KR20210029165 A KR 20210029165A KR 1020207038066 A KR1020207038066 A KR 1020207038066A KR 20207038066 A KR20207038066 A KR 20207038066A KR 20210029165 A KR20210029165 A KR 20210029165A
Authority
KR
South Korea
Prior art keywords
oxy
fluoro
mmol
group
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207038066A
Other languages
English (en)
Korean (ko)
Inventor
겐이치 요시다
고스케 다케우치
히데카즈 이노우에
히데아키 가게지
다카유키 모모세
게이스케 요시다
다케시 짐보
아키코 에가미
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20210029165A publication Critical patent/KR20210029165A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207038066A 2018-07-04 2019-07-03 비아릴에테르형 퀴나졸린 유도체 Withdrawn KR20210029165A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2018-127829 2018-07-04
JP2018127829 2018-07-04
PCT/JP2019/026483 WO2020009156A1 (ja) 2018-07-04 2019-07-03 ビアリールエーテル型キナゾリン誘導体

Publications (1)

Publication Number Publication Date
KR20210029165A true KR20210029165A (ko) 2021-03-15

Family

ID=69059535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207038066A Withdrawn KR20210029165A (ko) 2018-07-04 2019-07-03 비아릴에테르형 퀴나졸린 유도체

Country Status (15)

Country Link
US (1) US20230025510A1 (https=)
EP (1) EP3822263A4 (https=)
JP (1) JP7288904B2 (https=)
KR (1) KR20210029165A (https=)
CN (1) CN112334460A (https=)
AU (1) AU2019297889A1 (https=)
BR (1) BR112020027064A2 (https=)
CA (1) CA3105602A1 (https=)
CO (1) CO2021000800A2 (https=)
IL (1) IL279858A (https=)
MX (1) MX2021000014A (https=)
PH (1) PH12021550003A1 (https=)
SG (1) SG11202013218QA (https=)
TW (1) TW202012391A (https=)
WO (1) WO2020009156A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
US20230271936A1 (en) * 2020-08-10 2023-08-31 Abbisko Therapeutics Co., Ltd Efgr inhibitor, preparation method therefor and application thereof
WO2022105908A1 (zh) * 2020-11-23 2022-05-27 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
CN113264888A (zh) * 2021-03-04 2021-08-17 江苏康可得生物技术股份有限公司 酪氨酸激酶抑制剂及其药物应用
KR20230156767A (ko) * 2021-03-19 2023-11-14 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 퀴나졸린계 화합물, 조성물 및 퀴나졸린계 화합물의 적용
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
US20250136595A1 (en) * 2022-02-09 2025-05-01 Enliven Inc. Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
TW202404590A (zh) * 2022-04-05 2024-02-01 美商纜圖藥品公司 Ｅｇｆｒ抑制劑
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2025167927A1 (zh) * 2024-02-05 2025-08-14 苏州韬略生物科技股份有限公司 三取代喹唑啉衍生物及其酸加成盐及其药物组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150118A2 (en) 2007-06-05 2008-12-11 Hanmi Pharm. Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228446B1 (en) * 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
CA2527017A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
WO2013173254A1 (en) * 2012-05-14 2013-11-21 Dawei Zhang Bicyclic compounds as kinases inhibitors
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150118A2 (en) 2007-06-05 2008-12-11 Hanmi Pharm. Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Coussens L, et al.,Science. 1985 ; 230 (4730) : 1132 - 1139.
Das, M. et al., Proc. Natl Acad. Sci. USA, 74, 2790 - 2794 (1977).
Fukushige S et al., Mol Cell Biol 6 : 955 - 958, 1986.
Gravalos C, et al., Ann Oncol 19 : 1523 - 1529, 2008.
Hardwick R, et al., Eur. J Surg Oncol. 1997 (23) : 30 - 35.
Hyman D. M., et al., Nature. 2018 Feb 8 ; 554 (7691) : 189 - 194
Kancha, R. et al., Clin. Cancer Res. 15, 460 - 467 (2009).
Korkaya H, et al., Oncogene. 2008 ; 27 (47) : 6120 - 6130.
Lee, C. K. et al., J. Clin. Oncol. 33, 1958 - 1965 (2015).
Maria E. A. et al., Clin Cancer Res ; 18 (18) September 15, 2012
Oxnard G. R., J Thorac Oncol. 2013 Feb ; 8(2) : 179 - 184.
Pao, W. et al., PLoS Med. 2, e73 (2005).
Slamon DJ, et al., Science. 1987 ; 235 : 177 - 182.
Watanabe, S. et al., J. Thorac. Oncol. 9, 189 - 194 (2014).
Yano T, et al., OncolRep. 2006 ; 15 (1) : 65 - 71.
Yoshihisa K. et al., Cancer Sci, September 2016, 107 (9), 1179 - 1186

Also Published As

Publication number Publication date
PH12021550003A1 (en) 2021-09-20
IL279858A (en) 2021-03-01
AU2019297889A1 (en) 2021-02-18
EP3822263A1 (en) 2021-05-19
CA3105602A1 (en) 2020-01-09
JPWO2020009156A1 (ja) 2021-07-15
MX2021000014A (es) 2021-03-09
CO2021000800A2 (es) 2021-02-08
WO2020009156A1 (ja) 2020-01-09
EP3822263A4 (en) 2022-03-16
SG11202013218QA (en) 2021-02-25
CN112334460A (zh) 2021-02-05
TW202012391A (zh) 2020-04-01
US20230025510A1 (en) 2023-01-26
JP7288904B2 (ja) 2023-06-08
BR112020027064A2 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
KR20210029165A (ko) 비아릴에테르형 퀴나졸린 유도체
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
TWI585088B (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
CA2924705C (en) Quinazoline derivative and preparation method therefor
US20220041578A1 (en) Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
DK2707359T3 (en) SUBSTITUTED INDAZOLD DERIVATIVES ACTIVE AS KINase INHIBITORS
CN119490431A (zh) Tead转录因子的新型小分子抑制剂
EA027563B1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
BR112015019790B1 (pt) derivado de piridina monocíclica com ação inibidora de fgfr ou um sal farmaceuticamente aceitável do mesmo para uso médico
EP1559715B1 (en) N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
KR20180132664A (ko) 우레아 화합물, 이의 제조 방법 및 이의 의학적 용도
EP3590941B1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
CA3059283A1 (en) C5-anilinoquinazoline compounds and their use in treating cancer
JP2021165270A (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
KR20160133001A (ko) Tnks1 및/또는 tnks2의 억제제로서의 아미도-치환된 아졸 화합물
EP3760633B1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
JP7413346B2 (ja) ピロロピラゾール誘導体
HK40043221A (en) Biaryl ether-type quinazoline derivative
CN111620821A (zh) 取代的吡唑类化合物及包含该化合物的组合物及其用途
EP4570800A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
EP4467536A1 (en) Crystalline form of sulfur-containing isoindoline derivative
EP4538269A1 (en) Substituted pyridazine-3-carboxamide compound serving as tyk2 inhibitor
BR112017022243B1 (pt) Formas cristalinas do composto inibidor de fgfr4 cristalino, método para preparar uma forma cristalina e composição farmacêutica e usos terapêuticos das mesmas

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202